Erythromycin resistance in bacteria is primarily due to modifications in the ribosome, particularly in the 23S rRNA. The most common mechanism involves the action of methyltransferases, such as those encoded by the erm genes, which methylate adenine at position A2058 in the 23S rRNA. This modification prevents the binding of erythromycin and other MLS (macrolide-lincosamide-streptogramin) antibiotics, leading to resistance. Over 30 different erm genes have been identified, each associated with varying degrees of resistance. These genes are often found in clinical pathogens and actinomycetes. The MLS resistance mechanism includes resistance to macrolides, lincosamides, and streptogramins. The streptogramin family is divided into A and B groups, with resistance to B- and S-group streptogramins being conferred by the methylation of A2058. The binding sites of these antibiotics overlap or functionally interact, as evidenced by footprinting experiments showing that MLS antibiotics protect specific nucleotides in the 23S rRNA domain V from modification. Other resistance mechanisms include altered ribosomal proteins, such as L4 and L22 in E. coli, and mutations in the 23S rRNA that affect the peptidyltransferase center. These mutations can confer resistance to various MLS antibiotics. Additionally, some bacteria exhibit resistance through the active efflux of erythromycin and streptogramin B, as seen in certain strains. The Erm family of genes includes homologous methylases that use S-adenosylmethionine to methylate a single adenine residue in 23S rRNA. These methylases are classified into two groups: those that monomethylate adenine and those that dimethylate it. The presence of these methylases in various bacteria, including actinomycetes, highlights their importance in resistance mechanisms. The study of these resistance mechanisms has been facilitated by the identification of various erm genes and their associated mutations. The findings underscore the complex interplay between ribosomal structure and antibiotic resistance, with implications for the development of new antibiotics and the understanding of resistance patterns in clinical settings.Erythromycin resistance in bacteria is primarily due to modifications in the ribosome, particularly in the 23S rRNA. The most common mechanism involves the action of methyltransferases, such as those encoded by the erm genes, which methylate adenine at position A2058 in the 23S rRNA. This modification prevents the binding of erythromycin and other MLS (macrolide-lincosamide-streptogramin) antibiotics, leading to resistance. Over 30 different erm genes have been identified, each associated with varying degrees of resistance. These genes are often found in clinical pathogens and actinomycetes. The MLS resistance mechanism includes resistance to macrolides, lincosamides, and streptogramins. The streptogramin family is divided into A and B groups, with resistance to B- and S-group streptogramins being conferred by the methylation of A2058. The binding sites of these antibiotics overlap or functionally interact, as evidenced by footprinting experiments showing that MLS antibiotics protect specific nucleotides in the 23S rRNA domain V from modification. Other resistance mechanisms include altered ribosomal proteins, such as L4 and L22 in E. coli, and mutations in the 23S rRNA that affect the peptidyltransferase center. These mutations can confer resistance to various MLS antibiotics. Additionally, some bacteria exhibit resistance through the active efflux of erythromycin and streptogramin B, as seen in certain strains. The Erm family of genes includes homologous methylases that use S-adenosylmethionine to methylate a single adenine residue in 23S rRNA. These methylases are classified into two groups: those that monomethylate adenine and those that dimethylate it. The presence of these methylases in various bacteria, including actinomycetes, highlights their importance in resistance mechanisms. The study of these resistance mechanisms has been facilitated by the identification of various erm genes and their associated mutations. The findings underscore the complex interplay between ribosomal structure and antibiotic resistance, with implications for the development of new antibiotics and the understanding of resistance patterns in clinical settings.